Canadian Healthcare Company to Take Over Amdipharm Mercury for $1.9 Billion

Concordia Healthcare’s deal will further boost Amdipharm Mercury’s portfolio of drugs to 200 from 20 and will give a foothold in overseas markets.

Canada's Concordia Healthcare Corp to buy Amdipharm Mercury Ltd from private equity firm Cinven for $1.9 billion. This deal will further boost its portfolio of drugs to 200 from 20 and will give a foothold in overseas markets.

Amdipharm Mercury is a merger of Mercury Pharma and Amdipharm. It buys off-patent drugs from other pharma companies such as Novartis AG, GlaxoSmithKline Plc and Abbott Laboratories to sell them in 100 countries.

Canadian Pharmaceutical Company to Acquire Synergetics USA for $192 Million
Synergetics drug firm makes products used in surgeries on the back of the eye, as well as surgical equipments and other products.

Amdipharm's 190 drugs are used in several difficult-to-treat conditions including hyperthyroidism, depression and bacterial infections.

Concordia CEO Mark L Thompson, said, "This acquisition is a key milestone and pivotal turning point in Concordia's strategy, which gives us the platform to take our business to the next level. We are not only acquiring products and commercial infrastructure, but a seasoned management team who has done a fantastic job of building a solid and successful international pharma operation."

The deal is expected to boost Concordia's sales to about $870-$920 million in 2015 on a pro-forma basis, of which about $530-$560 million is expected to come from Amdipharm. The deal is expected to close in the fourth quarter of 2015.

Novartis Acquires Rights to GSK's Ofatumumab Drug For Multiple Sclerosis Treatment
The Swiss pharma will handle the worldwide development and commercialization of the drug - Ofatumumab - for use in multiple sclerosis, sources said.

John Beighton, Chief Executive Officer of AMCo, added, "We look forward to being part of the Concordia business – as the combination with AMCo is expected to create significant opportunities for further growth in the global pharmaceutical sector. We have a shared vision for growth that should greatly benefit employees and stakeholders of the combined business."

Source-Medindia

Health Canada Lifts 11-Month-Old Ban Against Two India-Based Pharmaceutical Plants
Two Bengaluru-based pharmaceutical plants were imposed a ban after inspectors from the US found that the staff had manipulated the data.

US-Based Company to Acquire a Rare Disease Company 'Scioderm' in Durham For $229 Million
Amicus Therapeutics a champion in the field of rare disease along with Scioderm aims to bring in a treatment for patients with epidermolysis bullosa in the US.